Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies

IMPORTANCE: Neurological complications are an increasingly recognized consequence of the use of anti–programmed death 1 (PD-1) antibodies in the treatment of solid-organ tumors, with an estimated frequency of 4.2%. To date, the clinical spectrum and optimum treatment approach are not established. OB...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JAMA neurology 2017-10, Vol.74 (10), p.1216-1222
Hauptverfasser:	Kao, Justin C, Liao, Bing, Markovic, Svetomir N, Klein, Christopher J, Naddaf, Elie, Staff, Nathan P, Liewluck, Teerin, Hammack, Julie E, Sandroni, Paola, Finnes, Heidi, Mauermann, Michelle L
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents - adverse effects Cohort Studies Electromyography Female Humans Male Middle Aged Neoplasms - drug therapy Nervous System Diseases - chemically induced Nervous System Diseases - diagnosis Nivolumab Online First Original Investigation Programmed Cell Death 1 Receptor - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!